Dr. Martens, a footwear expert, has gone into the red as its half-year revenue fell even more. According to actual currency rates, income decreased by 18 per cent for the 26 weeks ending 29th September 2024, totalling US $ 411.21 million.
In contrast, Adjust EBIT had a loss of US $ 5.45 million as opposed to a profit of US $ 50.29 million the previous year. Adjusted profit before tax also fell to a US $ 22.68 million loss, a drop on its earlier announced US $ 31.92 million profit. The company’s unadjusted pre-tax earnings dropped from a profit of US $ 32.68 million to a loss of US $ 36.36 million, resulting in an additional loss.
According to Dr. Martens’ report, the company’s direct-to-consumer revenue decreased by 7 per cent (or 5 per cent constant currency), while its wholesale revenue decreased by 29 per cent (or 27 per cent CC), “as expected.” E-commerce had a 4 per cent decline in revenue, while retail revenue within DTC declined 9 per cent.
Every region met the company’s performance standards. The Americas experienced the worst decline, with sales falling by 22 per cent. APAC saw a 12 per cent decline in revenues, while EMEA saw a 16 per cent decline.
But Dr. Martens remained hopeful about the future. The firm claimed that “swift action” had been taken to put in place a cost-cutting plan that, “at the top end of previous guidance,” would result in US $ 31.67 million in FY ’26.
